Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rinne, U. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rinne, U. K.
NEUROLOGY 1989;39:336
© 1989 American Academy of Neurology

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

U. K. Rinne, MD

Department of Neurology, University of Turku, Turku, Finland.

A randomized, prospective trial in 90 de novo parkinsonian patients showed that 4 years' treatment with lisuride resulted in significantly fewer end-of-dose disturbances and peak-dose dyskinesias, but also less improvement in parkinsonian disability, than with levodopa. Early combination of lisuride and a low dose of levodopa, during a 4-year follow-up, resulted in a therapeutic response equal to that achieved with high-dose levodopa alone, but significantly fewer end-of-dose failures and dyskinesias. Thus it seems advisable that treatment should begin in the early phase of the disease with a dopamine agonist such as lisuride combined with a low dose of levodopa.

Address correspondence and reprint requests to Dr. Rinne, Department of Neurology, University of Turku, SF-20520 Turku, Finland.

Received July 5, 1988. Accepted for publication in final form September 13, 1988.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. M. Miyasaki, W. Martin, O. Suchowersky, W. J. Weiner, and A. E. Lang
Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, January 8, 2002; 58(1): 11 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A Münchau and K P Bhatia
Pharmacological treatment of Parkinson's disease
Postgrad. Med. J., October 1, 2000; 76(900): 602 - 610.
[Full Text]

Home page
 NEJMHome page
O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, A. E. Lang, and The 056 Study Group
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa
N. Engl. J. Med., May 18, 2000; 342(20): 1484 - 1491.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. D. Korczyn, E. R. Brunt, J. P. Larsen, Z. Nagy, W. H. Poewe, and S. Ruggieri
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease
Neurology, July 1, 1999; 53(2): 364 - 364.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. Fahn
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Arch Neurol, May 1, 1999; 56(5): 529 - 535.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Yoshimura, E. Mizuta, O. Yoshida, and S. Kuno
Therapeutic Effects of Dopamine D1/D2 Receptor Agonists on Detrusor Hyperreflexia in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Parkinsonian Cynomolgus Monkeys
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 228 - 233.
[Abstract] [Full Text]

Home page
 BMJHome page
N. Quinn
Fortnightly Review: Drug treatment of Parkinson's disease
BMJ, March 4, 1995; 310(6979): 575 - 579.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by AAN Enterprises, Inc.